计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Information
Motixafortide (BL-8040, BKT140, TF 14016, 4-fluorobenzoyl, 4F-benzoyl-TN14003, T140) is an antagonist ofCXCR4with IC50 of ~1 nM. BL-8040 induces theapoptosisof AML blasts by down-regulatingERK,BCL-2,MCL-1andcyclin-D1via altered miR-15a/16-1 expression.
Targets
ERK ; Bcl-2 ; MCL-1 ; cyclin-D1 ; CXCR4 (Cell-free assay) ; 1 nM
In vitro
Treatment with BL-8040 induces the robust mobilization of AML blasts from the BM. In addition, AML cells exposed to BL-8040 undergoes differentiation. BL-8040 induces the apoptosis of AML cells in vitro. This apoptosis is mediated by the up-regulation of miR-15a/miR-16-1, resulting in down-regulation of the target genes BCL-2, MCL-1 and cyclin-D1. Overexpression of miR-15a/miR-16-1 directly induces leukemic cell death. BL-8040-induced apoptosis is also mediated by the inhibition of survival signals via the AKT/ERK pathways.
In vivo
BL-8040 induces the apoptosis of AML cells in vivo. Treatment with a BCL-2 inhibitor induces apoptosis and acts together with BL-8040 to enhance cell death. BL-8040 also synergizes with FLT3 inhibitors to induce AML cell death. Importantly, this combined treatment prolongs the survival of tumor-bearing mice and reduces minimal residual disease in vivo.
Cell Research(from reference)
Cell lines:The leukemic cell lines (MV4-11, THP-1, U937, HL-60)
Concentrations:0.1 μM, 1 μM, 10 μM, 20 μM
Incubation Time:24 h, 48 h
| IC50 | CXCR4, IC50: 1 nM |
|---|---|
| ALogP | -3.895 |
| hba_count | 17 |
| HBD Count | 30 |
| Rotatable Bond | 53 |